Several COVID-19 vaccines have been developed and authorized for emergency use by various regulatory agencies worldwide. Objective: to compare the adverse effects and safety of confirmed COVID-19 vaccines in Saudi Arabia and provide a centralized database of suspected adverse reactions and safety profiles to these vaccines. In this cross-sectional study, the study was conducted among the 633 vaccinated participants living in Saudi Arabia through an online questionnaire. Their age group was between 15-85 years old. The study indicated that 55% of the participants were infected with COVID-19, and 33% were infected before vaccination. 10% of our study participants had two or more related comorbidities, commonly hypertension, respiratory problems, and diabetes mellitus. The most frequent side effects of these vaccines are fatigue, headaches, fever, myalgia, arthralgia, pain, tenderness, and swelling at the injection site, especially after the first dose. Commonly systemic side effects presented in young female participants, 15-30 years old. This study postulates a database about the possibility of developing COVID-19 vaccine adverse effects based on age, gender, comorbidities, and vaccine type. More research must be done to understand more clearly the association between developing adverse effects and risk factors.
1. Postol OL, Shchadilova IS. Using Neuro-Stimulating Physical Exercises to Restore Cognitive Functions in the Correction of the Post-COVID Syndrome. J Biochem Technol. 2022;13(3):26-31. doi:10.51847/ugVSTNJDMP
2. Yin F, Ji M, Yang Z, Wu Z, Xia X, Xing T, et al. Exploring the determinants of global vaccination campaigns to combat COVID-19. Humanit Soc Sci Commun. 2022;9(1):1-3. doi:10.1057/s41599-022-01106-7
3. Food US. Drug Administration. Pfizer-BioNTech COVID-19 Vaccine. FDA, Fri. 2021;13:28.
4. Food US. Drug Administration Moderna COVID-19 Vaccine. 2021.
5. Butler R, MacDonald NE. Diagnosing the determinants of vaccine hesitancy in specific subgroups: The Guide to Tailoring Immunization Programmes (TIP). Vaccine. 2015;33(34):4176-9.
6. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020; 35:775-9.
7. Baden L, El Sahly H, Essink B. Učinkovitost in varnost cepiva mRNA-1273 SARS-CoV-2. N Engl J Med. 2021;384(5):403-16.
8. Voysey M, Clemens SC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Oxford COVID Vaccine Trial Group Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
9. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. ENSEMBLE Study Group: Safety and Efficacy of Single-Dose Ad26. COV2. S Vaccine against Covid-19. [Published online ahead of print April 21, 2021]. N Engl J Med.;10.
10. Polack F, Thomas S, Kitchin N. Sikkerhed og effektivitet af BNT162b2 mRNA Covid-19-vaccinen. N Engl J Med. Udgivet. 2020;10.
11. COVID C, Team R, Food and Drug Administration. Allergic reactions, including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14–23, 2020. Morb Mortal Weekly Rep. 2021;70(2):46.
12. Julianne G, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al. First month of COVID-19 vaccine safety monitoring—United States. US Dep Heal Hum Serv Dis Control Prev. 2021;70:283.
13. Shay DK. Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine—United States, March–April 2021. Morb Mortal Wkly Rep. 2021;70.
14. Walsh EE, Frenck Jr RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439-50.
15. Bakhuraysah MM. Immunity and Therapeutic Approaches against Coronavirus Disease 2019. Arch Pharm Pract. 2022;13(3).
16. El-Gamal F, Najm F, Najm N, Aljeddawi J. Visual Display Terminals Health Impact During COVID-19 Pandemic on the Population in Jeddah, Saudi Arabia. Entomol Appl Sci Lett. 2021;8(2):91-9. doi:10.51847/jJp0wj6I4S
17. Saudi Food and Drug Authority. Approved Registration of Pfizer-BioNTech COVID-19 Vaccine in the Kingdom of Saudi Arabia; 2020. Available from: https://www.spa.gov.sa/viewfullstory.php?lang=en&newsid=2166947. [Last accessed on 2021 Jan 10].
18. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States; 2020. Available from: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html. [Last accessed on 2021 Jan 10].
19. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16.
20. Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
21. Salman AH, Al-Gawhari FJ, Al-kinani KK. The effect of formulation and process variables on prepared etoricoxib Nanosponges. J Adv Pharm Educ Res. 2021;11(2):82-7. doi:10.51847/Q0QRKUV2kQ
22. Iqbal MM, Abid I, Hussain S, Shahzad N, Waqas MS, Iqbal MJ. The effects of regional climatic conditions on the spread of COVID-19 at a global scale. Sci Total Environ. 2020;739:140101.
23. Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305-6.
24. Plumly KM. Pharmacists as Immunizes: Increasing Non-influenza Adult Immunization Rates. Drew University; 2020.
25. Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111-6.
26. Tarbiah NI, Alkhattabi NA, Aldamen SA, Qutah BM, Al-Zahrani MH, Tayeb HO. Effect of Psychological Stress during the COVID-19 on Patients with Irritable Bowel Syndrome in Saudi Arabia. J Biochem Technol. 2021;12(3):14-21. doi:10.51847/b8QU0H2tMU
27. Wise J. Covid-19: People who have had an infection might only need one dose of mRNA vaccine. BMJ (Clinical research ed) 2021;372:n308.
28. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021;384(14):1372-4.
29. Riad A, Sağıroğlu D, Üstün B, Pokorná A, Klugarová J, Attia S, et al. Article Prevalence and risk factors of coronavac side effects: An independent cross-sectional study among healthcare workers in Turkey. J Clin Med. 2021;10(12):2629.
30. Gao YD, Agache I, Akdis M, Nadeau K, Klimek L, Jutel M, et al. The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19. Int Immunol. 2022;34(4):177-88.
31. Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S, et al. Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines. 2021;9(6):674.
32. Govindaraj A, Paulpandian SS, Shanmugam R. Comparative Evaluation of the Effect of Rind and Pulp Extract of Citrullus Lanatus on Streptococcus Mutans. Ann Dent Spec. 2022;10(4):34-9. doi:10.51847/OtdOtHZ09I
33. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939-49.
34. Kumar A, Raut A, Tripathi P, Banu N. Population Trend of Onion Thrips and Its Botanical Approach to Sustainable Management. Entomol Appl Sci Lett. 2022;9(3):25-31. doi:10.51847/LlgFcSiV6X
35. Thomas SJ, Moreira Jr ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761-73.
36. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979-93.
37. El-Shitany NA, Harakeh S, Badr-Eldin SM, Bagher AM, Eid B, Almukadi H, et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: a retrospective cross-sectional study. Int J Gen Med. 2021:1389-401.
38. Alhussain BS, Alfayez AA, Alduhaymi AA, Almulhim EA, Assiri MY, Ansari SH. Effect of Various Antibacterial Materials in Dental Composites: A Systematic Review. Ann Dent Spec. 2021;9(3):39-44. doi:10.51847/FlBp7cmL4q
39. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10(5):338-49.
40. Klein SL, Pekosz A. Sex-based biology and the rational design of influenza vaccination strategies. J Infect Dis. 2014;209(suppl_3): S114-9.
41. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-92.
42. Plumly KM. Pharmacists as Immunizes: Increasing Non-influenza Adult Immunization Rates. Drew University; 2020.
43. Hatmal MM, Al-Hatamleh MA, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, et al. Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting the severity of side effects. Vaccines. 2021;9(6):556.
44. Jayadevan R, Shenoy R, TS A. Survey of symptoms following COVID-19 vaccination in India. Medrxiv. 2021:2021-02
Copyright © 2024 Archives of Pharmacy Practice. Authors retain copyright of their article if they are accepted for publication.
Developed by Archives of Pharmacy Practice
